Skip to Content
Merck
All Photos(1)

Key Documents

SAB4700736

Sigma-Aldrich

Monoclonal Anti-CD34 antibody produced in mouse

clone 581, purified immunoglobulin, buffered aqueous solution

Synonym(s):

Anti-Mucosialin

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

mouse

conjugate

unconjugated

antibody form

purified immunoglobulin

antibody product type

primary antibodies

clone

581, monoclonal

form

buffered aqueous solution

species reactivity

human, nonhuman primates

concentration

1 mg/mL

technique(s)

flow cytometry: suitable
immunohistochemistry: suitable

isotype

IgG1

NCBI accession no.

UniProt accession no.

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

human ... CD34(947)

General description

The mouse monoclonal antibody 581 reacts with CD34 (Mucosialin), a 110-115 kDa monomeric transmembrane phosphoglycoprotein expressed on hematopoietic progenitors cells and on the most pluripotential stem cells; it is gradually lost on progenitor cells. The antibody recognizes the class III CD34 epitope resistant to neuraminidase, chymopapain and glycoprotease.
HLDA V.; WS Code MA27.

Immunogen

Human mucosialin

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Physical form

Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

10 - Combustible liquids

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Michael A Fischer et al.
European journal of nuclear medicine and molecular imaging, 41(8), 1563-1573 (2014-04-25)
The aim of this study was to prospectively monitor changes in the flow-metabolic phenotype (ΔFMP) of rectal carcinoma (RC) after neoadjuvant chemoradiotherapy (CRT) and to evaluate whether ΔFMP of RC correlate with histopathological prognostic factors including response to CRT. Sixteen
Ben Paylor et al.
Biochemical and biophysical research communications, 451(1), 148-151 (2014-07-30)
The cellular substrate underlying aberrant craniofacial connective tissue accumulation that occurs in disorders such as congenital infiltration of the face (CILF) remain elusive. Here we analyze the in vivo properties of a recently identified population of neural crest-derived CD31-:CD45-:alpha7-:Sca1+:PDGFRa+ fibro/adipogenic
Han Tang et al.
Medical oncology (Northwood, London, England), 31(6), 974-974 (2014-05-13)
Lysosome-associated protein transmembrane-4 beta (LAPTM4B) is a novel oncogene, which has been indicated to be dramatically overexpressed in various malignant tumors. The aims of this study were to detect LAPTM4B protein expression in patients with non-small cell lung cancer (NSCLC)
Lihua Zhu et al.
Neonatology, 106(2), 143-148 (2014-06-28)
Recombinant human erythropoietin (rh-EPO) has been used as a drug to treat premature infant anemia for over a decade. In addition to its erythropoietic effect, rh-EPO has also been reported to have protective effects against brain injury. Our aim was
Nasser M Malyar et al.
Cytotherapy, 16(9), 1270-1279 (2014-06-29)
The purpose of this study was to evaluate the effect of autologous bone marrow mononuclear cells (BM-MNCs) on symptoms and perfusion indices in severely symptomatic patients with peripheral arterial disease (PAD) without further option for endovascular or surgical revascularization. Only

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service